• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Reed-Lane

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Reed-Lane

    Syngene

    Emergent BioSolutions

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Drug Discovery Technology Trends

    Combining native mass spectrometry with fragment-based drug discovery in medicinal chemistry

    Drug Discovery Technology Trends
    Related CONTENT
    • Mogene
    • Vantage Solutions Supports FDA Pilot for Verification Router Service
    • Q BioMed, Chemveda Form Cancer Collaboration
    • Albemarle Expands RSM Capabilities
    • Lonza, Celltrion Sign Contract to Manufacture Remsima Drug Substance
    Sally-Ann Poulsen, Professor of Chemical Biology, Griffith Institute for Drug Discovery (GRIDD), Griffith University09.16.19
    For decades, high throughput screening (HTS) has been the go-to technique for early-stage drug discovery. This method enables researchers to rapidly identify large numbers of active compounds which could potentially influence a particular biological pathway of interest, and therefore progress through the lead discovery and target validation pipeline.

    Advanced laboratories are now using robotics for automated screening, to increase the overall speed of drug discovery. One such laboratory at the Griffith Institute for Drug Discovery (GRIDD), Griffith University, Brisbane, uses HTS robotics for both phenotypic screening—where the drug target is unknown —and target-based screening—where the protein of interest is known and the user is attempting to affect how it behaves, either by inhibiting or activating it. Another key research focus at GRIDD is the use of mass spectrometry (MS) in drug discovery, to observe small molecule protein interactions to identify better small molecules as starting points for drug discovery. This article highlights how our group has used MS together with fragment-based drug discovery (FBDD) as a powerful tool for discovering drug leads.

    Fragment based drug discovery
    Fragment-based screening (FBS) is now a widely applied method for the discovery of lead molecules in fragment-based drug discovery (FBDD) and complements HTS as one of the most popular method for screening molecules, however requiring significantly fewer compounds for screening. FBDD first identifies very small molecules (fragments), which are approximately half the size of standard drugs, and these fragments are expanded or linked together to generate drug leads.

    Bringing mass spectrometry to drug discovery
    At GRIDD, we have recently invested in Magnetic Resonance Mass Spectrometry (MRMS), formerly known as Fourier Transform Mass Spectrometry (FTMS), which has significantly improved fragment screening capabilities. The upper size limit of proteins that we can study in their native state has increased from 50 to 150 kilodaltons (kDa), and a high proportion of proteins in that size gap are of interest for drug discovery and are now accessible with this advanced technology.

    The extreme resolution of the MRMS instrument provides an extra layer of confidence in screening for weak interactions of fragments. The accurate identification of the binding and molecule mass for fragments is very important as a starting point in drug discovery. By combining MRMS technology with quadrupole time-of-flight (QTOF) MS, another filter of obtaining fragment binding data and ruling out ineffective compounds quickly, fragment screening is also achievable. The team then takes those compounds with binding potential over to the MRMS machine for higher resolution analysis.

    An additional benefit of the MRMS system is its minimal false positive results. Other techniques suffer from producing high false positives, because they are dealing with fragments at higher concentrations, which can aggregate and behave irregularly. When using MRMS, the fragment is at the same concentration as the protein, so false hits are less likely to occur. This is a big advantage, because if there are 1000 compounds screening in the library, only 200-300 might be filtered if there are a high number of false positives, rather than 10-30 true hits. The MRMS method avoids wasting valuable time on compounds that will not advance to drug discovery.

    Lowering attrition with FBDD
    It is becoming increasingly challenging to progress new drugs through the drug development process, and the rate of acceptance is declining. Investment by the pharmaceutical industry in small molecules to progress them to phase I, II and III clinical trials, before failing late in the process, is referred to as attrition, which is extremely costly. The drive to reduce attrition rates has drawn more attention to FBDD.

    The difference between fragment and traditional HTS is the molecular size. A fragment (or small molecule) is typically under 200 daltons (Da) in molecular weight, whereas a HTS compound is between 400-500 Da. The ability of a fragment to interact with a protein is less than a HTS compound and the binding affinity is weaker, but if an interaction occurs it indicates a perfect fit. This means that molecules resulting from FBDD workflows are likely to progress further in the clinical trial process and towards Food and Drug Administration (FDA) approval, or more likely to exit early and limit the investment knock, therefore lowering attrition rates.

    Combining fragment screening technologies
    Fragment screening has been a successful approach for FBDD researchers as there have been three approved drugs from the process, Vemurafenib (also known as Zelboraf), Venetoclax and Kisqali (LEE011, (ribociclib), with many more in phase I, II and III clinical trials.1 It is proving an area of great and growing interest for the pharmaceutical industry and in academic research. FBDD is, however, contingent on the development of analytical methods such as MS to be able to identify the weak binding fragments. As such, researchers at GRIDD are optimizing their workflows and combining techniques together with collaborators in order to give the best chance of accelerating drug discovery. Techniques for FBDD, in addition to MS, include Surface Plasmon Resonance (SPR), X‑ray Crystallography, Nuclear Magnetic Resonance (NMR) and Isothermal Titration Calorimetry (ITC). Each method has advantages and disadvantages but there is a need for multiple (orthogonal) methods, in order to be confident that a hit is a true hit.

    The group at GRIDD has combined native state MS with two proven and popular fragment screening methods, SPR and X-ray crystallography, in a fragment screening campaign against human carbonic anhydrase II (CA II).2 CA II is an enzyme which catalyzes the hydration of carbon dioxide, and defects are associated with diseases such as osteopetrosis (or “stone bone”) and renal tubular acidosis.3 The research recognized native state MS as a rapid, sensitive, high throughput, and label-free method to directly investigate protein−ligand interactions. However, there were few studies using this approach as a screening method to identify relevant protein−fragment interactions in FBDD. The results showed the first fragment screening analysis of electrospray ionization (ESI)-MS and NanoESI-MS using a high resolution Fourier-transform ion cyclotron resonance (FTICR) instrument (Bruker solariX XR 12.0T MRMS) in parallel with SPR as shown in Figure 1 and Table 1.


    Figure 1


    Table 1. Correlation of screening results for fragment hit chemotypes with surface plasmon resonance (SPR), electrospray ionization-mass spectrometry (ESI-MS), NanoESI-MS, and X-ray crystallography (green tick = hit, red cross = not a hit, n/a fragment not tested. aDose-response experiment performed at 25 degrees Celsius with a 5-point fragment concentration series range. bnano MS hit with ratio of unbound CA II:fragment bound CA II peak intensities in brackets.

    MS has a wide range of advantages over the other techniques, partly due to its speed and minimal sample requirement. For these reasons, GRIDD uses MS at the front end of the fragment screening cascade of methods, acting as a pre-filtering tool. Compounds for screening could start at, for example, 1000 for MS, and be brought down to 50 for the subsequent techniques, or MS could be used standalone in the workflow.

    Quantitative native MS
    The group at GRIDD has recently identified a new zinc binder fragment, in collaboration with the Commonwealth Scientific and Industrial Research Organization (CSIRO),4 which is a potent inhibitor of CA II. SPR and native ESI-MS identified compound 10, which has an affinity and ligand efficiency approaching that of sulfonamides, a well-known class of zinc binder for CA II.

    The group determined the crystal structure of compound 10 bound to CA II, confirming the binding pose of the new fragment to CA II, which included a primary interaction with the zinc and two hydrogen bonds with the protein, therefore explaining the high affinity as seen in Figure 2.


    Figure 2

    The study used a series of 18 analogues of compound 10 to assess the structure-activity relationship (SAR) using both SPR and MS. The group was able to obtain quantitative MS data by holding protein concentration constant (at 14.5 µM) and varying the fragment concentration from 0.5 – 120 µM. Plotting the percentage of protein bound and curve-fitting revealed dissociation constants remarkably similar to those determined using SPR. Nine of the new fragments showed at least some activity, although none were significantly more potent than compound 10. Crystal soaking experiments led to seven new structures, with all fragments binding in a similar manner as compound 10.

    The future of FBDD
    Collaboration with industry is a key focus for many academic research institutions, as there is a growing interest from the pharmaceutical sector in FBDD to aid drug discovery. Such industry-academia relationships, as well as the advances in analytical technology such as MRMS have made it possible to discover otherwise overlooked drug leads. 

    References
    1. Singh M, Tam B and Akabayov B. (2018) NMR-Fragment Based Virtual Screening: A Brief Overview, Molecules,  23, 233.
    2. Woods L, Dolezal O, Ren B, Ryan J, Peat T, Poulsen S. (2016) Native State Mass Spectrometry, Surface Plasmon Resonance, and X‑ray Crystallography Correlate Strongly as a Fragment Screening Combination, Journal for Medical Chemistry, 59, 5, 2192-2204
    3. Roth DE, Venta PJ, Tashian RE, and Sly WS. (1992) Molecular basis of human carbonic anhydrase II deficiency, Proc Natl Acad Sci USA, 89(5): 1804–1808.
    4. Chrysanthopoulos P, Mujumdar P, Woods L, Dolezal O, Ren B, Peat T and Poulsen S. (2017) Identification of a New Zinc Binding Chemotype by Fragment Screening, Journal for Medical Chemistry, 60, 7333−7349.

    Professor Sally-Ann Poulsen, Professor of Chemical Biology at Griffith Institute for Drug Discovery (GRIDD), Griffith University, introduced MRMS (FTMS) use for the study of protein-ligand complexes to Australia, and was one of the first researchers worldwide, and the first in Australia, to utilize native state mass spectrometry to screen fragments by the direct observation of protein-ligand complexes.      
    Related Searches
    • Clinical Trials
    • study
    • discovery
    • pipeline
    Suggested For You
    Mogene Mogene
    Vantage Solutions Supports FDA Pilot for Verification Router Service Vantage Solutions Supports FDA Pilot for Verification Router Service
    Q BioMed, Chemveda Form Cancer Collaboration Q BioMed, Chemveda Form Cancer Collaboration
    Albemarle Expands RSM Capabilities Albemarle Expands RSM Capabilities
    Lonza, Celltrion Sign Contract to Manufacture Remsima Drug Substance Lonza, Celltrion Sign Contract to Manufacture Remsima Drug Substance
    Critical Factors of Fill Finish Manufacturing For Biologics Critical Factors of Fill Finish Manufacturing For Biologics
    EAG Launches New Laboratory in China EAG Launches New Laboratory in China
    Embracing Risk-Based Monitoring: The Pivotal Role of Tools and Technologies  Embracing Risk-Based Monitoring: The Pivotal Role of Tools and Technologies
    Skyhawk, Genentech Enter Exclusive Multi-target RNA Alliance Skyhawk, Genentech Enter Exclusive Multi-target RNA Alliance
    Rafael Pharma Signs License Agreement with Ono Pharmaceutical Rafael Pharma Signs License Agreement with Ono Pharmaceutical
    New Drug Development Strategies Needed for Alzheimer’s Treatments New Drug Development Strategies Needed for Alzheimer’s Treatments
    CPhI NA Keynotes: Former Senator Jeff Flake & Numerate CTO Brandon Allgood CPhI NA Keynotes: Former Senator Jeff Flake & Numerate CTO Brandon Allgood
    Piramal Pharma Solutions Piramal Pharma Solutions
    Charles River & CHDI Extend Partnership Charles River & CHDI Extend Partnership
    Eurofins Discovery Launches DiscoveryOne Eurofins Discovery Launches DiscoveryOne

    Related Features

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • Drug Discovery
      How Can We Predict Immunogenicity Earlier in Drug Discovery?

      How Can We Predict Immunogenicity Earlier in Drug Discovery?

      Identifying potential immune responses earlier in the development of biotherapeutics.
      Kevin Merlo and Tim Moran, Dassault Systèmes Biovia 09.01.17

    • Analytical Services | Drug Development | Drug Discovery | Preclinical Outsourcing | R&D
      The Human Parts of Mouse Models

      The Human Parts of Mouse Models

      The PDX model system has come back into focus
      Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company 10.11.16


    • APIs | Cleaning Validation | Clinical Trials | Drug Development | Drug Discovery | Risk Management | Toxicology | Validation
      Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

      Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

      Health-based exposure limits are needed to support risk assessments
      B.D. Naumann, P.J. Nigro, U. Bruen, L. Parola, D. Cragin and A. Schatz, Merck & Co., Inc. and Ashland, Inc. 05.05.16

    • Capsules | cGMP Manufacture | Clinical Trials | Drug Development | Drug Discovery | Excipients | Facilities | Formulation Development
      Solid Dispersions

      Solid Dispersions

      A universal formulation strategy for poorly soluble drugs?
      Robert Harris, Juniper Pharma Services 04.05.16

    • Clinical Trials | Cold Chain Management | Drug Development | Drug Discovery | Laboratory Testing | Logistics | Supply Chain

      Cold-Chain Logistics & The Central Lab

      Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity
      Kristin Brooks, Associate Editor 01.28.16


    • Bioassay Development | Clinical Trials | Drug Development | Drug Discovery | Microbiology | Toxicology | Validation
      Fit-For-Purpose Assay Development in Bioanalysis

      Fit-For-Purpose Assay Development in Bioanalysis

      The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.
      Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience 01.28.16

    • Clinical Trials | Drug Discovery
      Bringing Transparency and Collaboration to CRO Oversight

      Bringing Transparency and Collaboration to CRO Oversight

      Relationships between sponsors and CROs are getting stronger
      Craig Morgan , goBalto Inc. 11.17.15

    • Biologics, Proteins, Vaccines | Biosimilars | cGMP Manufacture | Clinical Trials | Drug Delivery | Drug Development | Drug Discovery | Facilities | Formulation Development | GMPs/GCPs | Information Technology | Preclinical Outsourcing | QA/QC | R&D | Regulatory Affairs
      Top 25 Pharma and Biopharma Report

      Top 25 Pharma and Biopharma Report

      (Based on 2014 Sales, in $U.S. Millions)
      07.20.15


    • APIs | Bioassay Development | Capsules | Chemistry | Drug Development | Drug Discovery | Excipients | Extractables and Leachables | Facilities | Fill/Finish | Formulation Development | GMPs/GCPs | Lyophilization | Methods Development | Process Development | Process Validation | QA/QC | Solid Dosage/Semi-solids | Supply Chain | Toxicology | Validation
      Continuous Process in Pharmaceutical Manufacturing: Considerations, Nuances and Challenges

      Continuous Process in Pharmaceutical Manufacturing: Considerations, Nuances and Challenges

      A review of the business and process considerations for continuous processing in pharma manufacturing
      Girish Malhotra, EPCOT International 06.02.15

    • Bioassay Development | Drug Development | Drug Discovery | GMPs/GCPs | Inspections | Methods Development | Process Development | Regulatory Affairs | Toxicology
      Moore’s Law for More Health

      Moore’s Law for More Health

      This year marks the semicentennial anniversary of a prediction about exponential growth and productivity
      Patrick Jordan , Encore Health Resources 06.02.15

    • APIs | Clinical Trials | Drug Discovery | Industry News
      Consolidation in Outsourcing

      Consolidation in Outsourcing

      Reviewing 2014’s M&A activity
      Michael A. Martorelli , Director, Fairmount Partners 03.06.15


    • Chemistry | Clinical Trials | Drug Discovery | Preclinical Outsourcing | R&D | Validation
      Jump Starting the Non-Profit Research Engine

      Jump Starting the Non-Profit Research Engine

      How CROs are teaming up with disease foundations to accelerate drug discovery.
      Kate Hilyard , Managing Director, BioFocus 01.29.15

    • Bioassay Development | Chemistry | Clinical Trials | Drug Development | Drug Discovery | Methods Development | Microbiology | Process Development | R&D | Toxicology | Validation
      Streamlining Antibiotic Development

      Streamlining Antibiotic Development

      Looking at the role of the central microbiology laboratory.
      Suzanne E. Dale, Ph.D., D(ABMM) , ACM Global Central Laboratory 11.13.14

    • Chemistry | Clinical Trials | Drug Delivery | Drug Development | Drug Discovery | Formulation Development | Logistics | R&D | Supply Chain | Toxicology
      Adoption of FTE Contracts in R&D Outsourcing: Present and Future

      Adoption of FTE Contracts in R&D Outsourcing: Present and Future

      Pharma is looking for more R&D externalization for cost savings through FTE engagement.
      Sarabjeet Singh Sharad , Beroe Inc. 11.13.14

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login